Nav: Home

New study identifies biomarker that may indicate risk of atrial fibrillation

May 11, 2017

Researchers have identified a microRNA biomarker that demonstrates a strong association with the incidence of atrial fibrillation, the most common abnormal heart rhythm that affects more than 2.7 million Americans.

The researchers from the Intermountain Medical Center Heart Institute in Salt Lake City have been seeking microRNA biomarkers to guide the diagnosis and potential treatment of troublesome heart conditions including atrial fibrillation and heart failure.

For the study, the researchers sought biomarkers that could specifically predict the occurrence and severity of atrial fibrillation, said the study's lead author, Oxana Galenko, PhD, clinical research senior scientist in cardiovascular research at Intermountain Medical Center Heart Institute.

"We wanted to generate specific profiles of the molecules and see if they could be used to distinguish between the risk of atrial fibrillation in different groups of patients," Galenko said.

The research team identified microRNAs, small, stable, noncoding RNA molecules that negatively control gene expression at a stage called the post-transcriptional level. These markers could potentially indicate which atrial fibrillation patients are most likely to benefit from ablation - a procedure that creates tissue scarring around the pulmonary veins and prevents electrical impulses from being misdirected, which can cause atrial fibrillation.

Researchers will present results of the study at Heart Rhythm 2017, the Heart Rhythm Society's 38th Annual Scientific Sessions, in Chicago on Thursday, May 11, 2017.

Atrial fibrillation is characterized by a rapid and irregular heartbeat caused when the top chambers of the heart quiver erratically, sometimes faster than 200 times per minute. The condition can have a significant negative impact on an individual's quality of life, causing heart palpitations, chronic fatigue, debilitating pain and can increase the risk of stroke fivefold.

"From the research, we knew certain markers that were cited mostly for heart failure patients, so we knew which microRNAs we were going to look at, because we've looked at them before," said Victoria Jacobs, NP, PhD, a member of the research team.

Atrial fibrillation has four subtypes, with two most common: Paroxysmal AF is episodic, while persistent AF lasts and has different degrees of severity. The researchers hoped to identify specific microRNAs involved in atrial fibrillation, with an eye toward using them to discriminate between the two subtypes.

The Intermountain Medical Center Heart Institute maintains an extensive bio bank that contains a large amount of biological and medical data that's collected by taking a small amount of blood from consenting patients, then banking those samples for future research.

For the study, researchers used very small amounts of plasma from the bio bank. Because microRNAs are so small and stable, they can be detected in circulating biological fluids like saliva and blood.

The researchers examined samples from 140 atrial fibrillation patients -- 93 paroxysmal and 47 persistent-- and 50 people with no identified heart disease who served as a control group.

Researchers then examined several miRs that had been associated with atrial fibrillation, including 21, 291, 133a, 133b, 150 and 328. They were able to narrow it to miR 21.

Researchers looked specifically at the concentration of microRNAs in the patients' circulating blood and found that risk of atrial fibrillation increased as levels of miR 21 decreased. While having low levels of the microRNA appears to be strongly associated with the development of atrial fibrillation, it wasn't associated with any differences between paroxysmal and persistent AF.

The researchers believe that means the mechanism of how the disease occurs and its progression are different. In future studies, they hope to find out what initiates the disease.

"As atrial fibrillation progresses, we know there's more fibrosis in the left atrium," said Dr. Jacobs. "We have theories of what causes the harmful fibrosis, including which pathways are activated to causes fibrosis. But we really don't know the cause yet. It's unclear if the microRNA carries the signals then it progresses to fibrosis or vice versa."
-end-
Other researchers involved in the study include Madisyn Taylor; Matt Grover; Stacey Knight, PhD; Michael Cutler, DO, PhD; Brent Muhlstein, MD; John Carlquist, PhD; Kirk Knowlton, MD; and Jared Bunch, MD.

The Intermountain Medical Center Heart Institute is part of the Intermountain Healthcare system, which is based in Salt Lake City.

Intermountain Medical Center

Related Atrial Fibrillation Articles:

Sleep apnea may increase atrial fibrillation risk
Obstructive sleep apnea (OSA) may increase the risk of developing atrial fibrillation (AF), according to new research presented at the ATS 2017 International Conference.
New study identifies biomarker that may indicate risk of atrial fibrillation
Researchers have identified a microRNA biomarker that demonstrates a strong association with the incidence of atrial fibrillation, the most common abnormal heart rhythm.
More women with atrial fibrillation die after ER discharge than men
A new study from the University of Alberta adds to the growing evidence that women with cardiovascular disease may receive different health care from men -- and experience worse outcomes.
Big women have nearly threefold greater risk of atrial fibrillation
Big women have a nearly threefold greater risk of atrial fibrillation than small women, according to research presented today at EuroPrevent 2017.
Most atrial fibrillation patients don't get preventive drug before stroke
More than 80 percent of stroke patients with a history of atrial fibrillation either received not enough or no anticoagulation therapy prior to having a stroke, despite the drugs' proven record of reducing stroke risk, according to a Duke Clinical Research Institute study.
More than half of atrial fibrillation patients become asymptomatic after catheter ablation
More than half of patients with atrial fibrillation become asymptomatic after catheter ablation, reports the largest study of the procedure published today in European Heart Journal.
Medication adherence a problem in atrial fibrillation patients
Anticoagulant therapy is important for stroke prevention in people with atrial fibrillation, but a new study shows many people don't stick with it.
Atrial fibrillation patients are at increased risk of dementia, regardless of anticoagulation use
Atrial fibrillation patients who use the drug, warfarin, to prevent harmful blood clots from forming in their hearts to lower risk of stroke are at higher risk of developing dementia than patients who use warfarin for non-atrial fibrillation conditions, according to a new study from the Intermountain Medical Center Heart Institute.
iPhone camera application may detect atrial fibrillation
A smartphone application made it possible to use the iPhone camera to detect atrial fibrillation via facial signals and without physical contact, according to a preliminary study presented at the American Heart Association's Scientific Sessions 2016.
Study reports progress in preventing bleeding in atrial fibrillation
A new study led by clinician-researchers at Beth Israel Deaconess Medical Center testing the safety and effectiveness of anticoagulant strategies for patients with atrial fibrillation who undergo stenting procedures has shown that therapies combining the anticoagulant drug rivaroxaban with either single or dual anti-platelet therapy were more effective in preventing bleeding complications than the current standard of care.

Related Atrial Fibrillation Reading:

Best Science Podcasts 2019

We have hand picked the best science podcasts for 2019. Sit back and enjoy new science podcasts updated daily from your favorite science news services and scientists.
Now Playing: TED Radio Hour

Jumpstarting Creativity
Our greatest breakthroughs and triumphs have one thing in common: creativity. But how do you ignite it? And how do you rekindle it? This hour, TED speakers explore ideas on jumpstarting creativity. Guests include economist Tim Harford, producer Helen Marriage, artificial intelligence researcher Steve Engels, and behavioral scientist Marily Oppezzo.
Now Playing: Science for the People

#524 The Human Network
What does a network of humans look like and how does it work? How does information spread? How do decisions and opinions spread? What gets distorted as it moves through the network and why? This week we dig into the ins and outs of human networks with Matthew Jackson, Professor of Economics at Stanford University and author of the book "The Human Network: How Your Social Position Determines Your Power, Beliefs, and Behaviours".